IIM
CRVS icon

INTECH Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

INTECH Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$342K Sell
23,381
-12,592
-35% -$201K ﹤0.01% 1511
2025
Q4 		$277K Buy
35,973
+9,812
+38% +$77.4K ﹤0.01% 1800
2025
Q3 		$193K Buy
26,161
+383
+1% +$1.96K ﹤0.01% 2084
2025
Q2 		$103K Buy
+25,778
New +$93.8K ﹤0.01% 2284

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

INTECH Investment Management's CRVS Position: Q1 2026 in Review

INTECH Investment Management reduced its Corvus Pharmaceuticals (CRVS) stake by 35% in Q1 2026, selling an estimated $201K and leaving 23,381 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

INTECH Investment Management first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • INTECH Investment Management held 23,381 shares of Corvus Pharmaceuticals worth $342K as of Q1 2026.
  • INTECH Investment Management sold 12,592 Corvus Pharmaceuticals shares in Q1 2026, an estimated $201K.
  • Corvus Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1511 holding.
  • INTECH Investment Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.